Monthly News Roundup - August 2022
FDA Approves Auvelity, a Novel and Rapid-Acting Antidepressant  In August, the FDA approved Auvelity (dextromethorphan and bupropion) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. Auvelity, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves'Rapid-Acting' Oral Drug for Major Depression FDA Approves'Rapid-Acting' Oral Drug for Major Depression
The US Food and Drug Administration has approved dextromethorphan-bupropion (Auvelity), the first for an NMDA receptor antagonist for the treatment of major depressive disorder in adults.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 22, 2022 Category: Internal Medicine Tags: Psychiatry News Alert Source Type: news

FDA Approves Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder in Adults
Auvelity is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week11-4 Auvelity uses the first new oral mechanism of action... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 20, 2022 Category: Drugs & Pharmacology Source Type: news

FDA OKs First Oral NMDA Receptor Antagonist for Depression
(MedPage Today) -- The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday. Dextromethorphan-bupropion is an oral... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 19, 2022 Category: Psychiatry Source Type: news

Granules India gets USFDA nod for generic antidepressant drug
"We are pleased to receive approval of Bupropion Hydrochloride (XL) tablet product within first review cycle of 10 months from filing date. This product will be a valuable addition to our growing modified release product portfolio in the US market," GPI Executive Director Priyanka Chigurupati stated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2022 Category: Pharmaceuticals Source Type: news

Adverse effects associated with bupropion therapeutic errors in adults reported to four United States poison centers - Beuhler MC, Spiller HA, Alwasiyah D, Bassett R, Trella J, Huecker M, Webb AN.
CONTEXT: Bupropion is a frequently used medication. Excessive doses may cause altered mental status, seizures, and dysrhythmias. There is a need for accurate estimate of seizure risk with therapeutic errors and determination if minor symptoms are harbinger... (Source: SafetyLit)
Source: SafetyLit - November 25, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

' Impressive' Results for Novel Antidepressant, So Why the FDA Delay?'Impressive' Results for Novel Antidepressant, So Why the FDA Delay?
AXS-05, a combination of dextromethorphan and bupropion, appears to have a rapid and durable effect in major depression, yet its new drug application remains in FDA limbo.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 13, 2021 Category: Neurology Tags: Psychiatry News Source Type: news

The timing of clinical effects of bupropion misuse via insufflation reported to a regional poison center - McCabe DJ, McGillis E, Willenbring BA.
BACKGROUND: Bupropion is an antidepressant medication with expanding indications including smoking cessation, weight loss, attention-deficit/hyperactivity disorder, seasonal affective disorder, and amphetamine dependence. Despite its increasing popularity ... (Source: SafetyLit)
Source: SafetyLit - September 22, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Antidepressant Shines in Phase 2 Trial, but FDA Voices Concerns Antidepressant Shines in Phase 2 Trial, but FDA Voices Concerns
Although an antidepressant combining dextromethorphan and bupropion delayed time to depression relapse in a phase 2 trial, its upcoming FDA action date may be in jeopardy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 11, 2021 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Back from the dead: a case of bupropion overdose mimicking brain death - Pelletier JN, Ie SR, Stromberg PE, Perkins JC.
We describe a case of a 43-year-old female who was found unresponsive after an intentional overdose of bupropion and cyclobenzaprine. Upon transfer to our hospital she began to exhibit signs of Brain Death (BD). Electroencephalogram (EEG) showed burst supp... (Source: SafetyLit)
Source: SafetyLit - April 17, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Clinical effects of intravenous bupropion misuse reported to a regional poison center - McCabe DJ, McGillis E, Willenbring BA.
Bupropion is an antidepressant medication with expanding indications including smoking cessation, weight loss, attention-deficit/hyperactivity disorder, seasonal affective disorder, and amphetamine dependence. Despite its increasing popularity among provid... (Source: SafetyLit)
Source: SafetyLit - April 5, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Bupropion - Naltrexone Bests Placebo in Methamphetamine Use Disorder
Response was low but higher with naltrexone - bupropion than placebo during 12 - week, two - stage trial (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - January 15, 2021 Category: Psychiatry Tags: Pharmacy, Psychiatry, Journal, Source Type: news

Bupropion-Naltrexone Bests Placebo in Methamphetamine Use Disorder
FRIDAY, Jan. 15, 2021 -- For adults with methamphetamine use disorder, response is higher with receipt of extended-release injectable naltrexone plus oral extended-release bupropion versus placebo, according to a study published in the Jan. 14 issue... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Naltrexone and Bupropion Promising Combo for Meth Addiction Naltrexone and Bupropion Promising Combo for Meth Addiction
The combination treatment may be a game changer for some patients with severe methamphetamine use disorder, results of a new randomized trial, ADAPT-2, suggest.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2021 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Relapse prevention interventions for smoking cessation
Updated review found that behavioural interventions provided no worthwhile benefit in preventing relapse in assisted abstainers. Moderate certainty evidence suggests that extended treatment with varenicline but not bupropion helped to prevent relapse. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 21, 2020 Category: Consumer Health News Source Type: news